There is research on this stock available only to PRO subscribers.
Yesterday, 1:12 PM
Mon, Oct. 13, 12:46 PM
Wed, Oct. 8, 9:10 AM
Wed, Oct. 8, 7:42 AM
- The USPTO issues six patents to Vical (NASDAQ:VICL) covering its DNA vaccines for herpes simplex virus type 2 (HSV-2) containing specific gene sequences and formulated with its Vaxfectin adjuvant. The IP is jointly owned by the company and the University of Washington.
- The patents cover composition of matter of plasmid DNA vaccines encoding several HSV-2 antigens, including envelope and tegument viral proteins, separately or in combination, and formulated with the Vaxfectin adjuvant.
- The new patents add to Vical's patent estate that is based on its discovery that administering genetic sequences without the use of viral vectors will result in expression of the proteins encoded by the sequences.
Thu, Jul. 31, 8:25 AM
Thu, Jul. 31, 6:10 AM
Thu, May. 1, 6:41 AM
Wed, Feb. 12, 9:10 AM
Wed, Feb. 12, 6:31 AM| Comment!
Wed, Feb. 12, 12:05 AM
Tue, Feb. 11, 5:30 PM
Dec. 17, 2013, 2:17 PM
- Vical (VICL +2.5%) initiates a Phase 1/2 study of a Vaxfectin (an adjuvant) -formulated HSV-2 vaccine.
- The company hopes the vaccine can reduce viral shedding by "harnessing the immune system [thus] freeing subjects from daily, lifelong antiviral drug usage." (PR)
- As for market potential, SA contributor Theodore Cohen says "current estimates suggest that a therapeutic HSV-2 vaccine could generate as much as a billion dollars in annual sales at its peak."
- For more on VICL's work on HSV-2, see Cohen's September piece here.
Oct. 31, 2013, 6:33 AM
Aug. 23, 2013, 3:44 PM
- Vical (VICL +2%) gains after disclosing plans late yesterday to lay off 39% of its workforce after scrapping its cancer immunotherapy program to instead focus on infectious disease vaccines.
- The company expects to incur around $2.2M in restructuring charges during Q3, with 47 employees being cut.
- The move follows last week's report that it was halting the development of Allovectin, after its investigational cancer immunotherapy failed to meet efficacy endpoints in recent Phase III clinical testing.
- The company says it had around $70M in cash and equivalents on hand at the end of the June quarter, giving it enough resources to continue operations at least through 2015.
- Net cash burn rate was about $17M in Q2, down about $1M from the prior quarter.
Aug. 12, 2013, 12:59 PM
Aug. 12, 2013, 9:12 AM
VICL vs. ETF Alternatives
Other News & PR